Literature DB >> 30536290

Noncoding RNA in Cholangiocarcinoma.

Massimiliano Salati1,2, Chiara Braconi1,3.   

Abstract

Cholangiocarcinomas (CCAs) are tumors with a dismal prognosis. Early diagnosis is a key challenge because of the lack of specific symptoms, and the curability rate is low due to the difficulty in achieving a radical resection and the intrinsic chemoresistance of CCA cells. Noncoding RNAs (ncRNAs) are transcripts that are not translated into proteins but exert their functional role by regulating the transcription and translation of other genes. The discovery of the first ncRNA dates back to 1993 when the microRNA (miRNA) lin-4 was discovered in Caenorhabditis elegans. Only 10 years later, miRNAs were shown to play an oncogenic role in cancer cells and within 20 years miRNA therapeutics were tested in humans. Here, the authors review the latest evidence for a role for ncRNAs in CCA and discuss the promise and challenges associated with the introduction of ncRNAs into clinical practice. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30536290     DOI: 10.1055/s-0038-1676097

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  10 in total

Review 1.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

Authors:  Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-06-30       Impact factor: 46.802

Review 2.  Cholangiocarcinoma: novel therapeutic targets.

Authors:  Keisaku Sato; Shannon Glaser; Domenico Alvaro; Fanyin Meng; Heather Francis; Gianfranco Alpini
Journal:  Expert Opin Ther Targets       Date:  2020-02-26       Impact factor: 6.902

Review 3.  Current challenges to underpinning the genetic basis for cholangiocarcinoma.

Authors:  Antonio Cigliano; Xin Chen; Diego F Calvisi
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2021-04-23       Impact factor: 3.869

4.  Modulation of Biliary Cancer Chemo-Resistance Through MicroRNA-Mediated Rewiring of the Expansion of CD133+ Cells.

Authors:  Pietro Carotenuto; Somaieh Hedayat; Matteo Fassan; Vincenzo Cardinale; Andrea Lampis; Vincenza Guzzardo; Caterina Vicentini; Aldo Scarpa; Luciano Cascione; Daniele Costantini; Guido Carpino; Domenico Alvaro; Michele Ghidini; Francesco Trevisani; Robert Te Poele; Massimiliano Salati; Sofia Ventura; Georgios Vlachogiannis; Jens C Hahne; Luke Boulter; Stuart J Forbes; Rachel V Guest; Umberto Cillo; Ian Said-Huntingford; Ruwaida Begum; Elizabeth Smyth; Vasiliki Michalarea; David Cunningham; Lorenza Rimassa; Armando Santoro; Massimo Roncalli; Vladimir Kirkin; Paul Clarke; Paul Workman; Nicola Valeri; Chiara Braconi
Journal:  Hepatology       Date:  2020-09-10       Impact factor: 17.425

Review 5.  Molecular heterogeneity in intrahepatic cholangiocarcinoma.

Authors:  Keun Soo Ahn; Koo Jeong Kang
Journal:  World J Hepatol       Date:  2020-12-27

6.  Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage.

Authors:  Pietro Carotenuto; Francesco Amato; Andrea Lampis; Colin Rae; Somaieh Hedayat; Maria C Previdi; Domenico Zito; Maya Raj; Vincenza Guzzardo; Francesco Sclafani; Andrea Lanese; Claudia Parisi; Caterina Vicentini; Ian Said-Huntingford; Jens C Hahne; Albert Hallsworth; Vladimir Kirkin; Kate Young; Ruwaida Begum; Andrew Wotherspoon; Kyriakos Kouvelakis; Sergio Xavier Azevedo; Vasiliki Michalarea; Rosie Upstill-Goddard; Sheela Rao; David Watkins; Naureen Starling; Anguraj Sadanandam; David K Chang; Andrew V Biankin; Nigel B Jamieson; Aldo Scarpa; David Cunningham; Ian Chau; Paul Workman; Matteo Fassan; Nicola Valeri; Chiara Braconi
Journal:  Nat Commun       Date:  2021-11-18       Impact factor: 14.919

7.  Development and Multicentre Validation of the Modena Score to Predict Survival in Advanced Biliary Cancers Undergoing Second-Line Chemotherapy.

Authors:  Massimiliano Salati; Luigi Marcheselli; Carlo Messina; Valeria Merz; Marco Messina; Pietro Carotenuto; Francesco Caputo; Fabio Gelsomino; Andrea Spallanzani; Luca Reggiani Bonetti; Stefania Caramaschi; Gabriele Luppi; Massimo Dominici; Michele Ghidini
Journal:  Cancer Manag Res       Date:  2022-03-05       Impact factor: 3.989

8.  Long non-coding RNA titin-antisense RNA1 contributes to growth and metastasis of cholangiocarcinoma by suppressing microRNA-513a-5p to upregulate stratifin.

Authors:  Yang Liu; Jiangyang Sun; Peng Qi; Yang Liu
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

Review 9.  Emerging Role of microRNA Dysregulation in Diagnosis and Prognosis of Extrahepatic Cholangiocarcinoma.

Authors:  Christian Prinz; Robin Frese; Mashiba Grams; Leonard Fehring
Journal:  Genes (Basel)       Date:  2022-08-19       Impact factor: 4.141

Review 10.  Current Advances in Basic and Translational Research of Cholangiocarcinoma.

Authors:  Keisaku Sato; Leonardo Baiocchi; Lindsey Kennedy; Wenjun Zhang; Burcin Ekser; Shannon Glaser; Heather Francis; Gianfranco Alpini
Journal:  Cancers (Basel)       Date:  2021-07-01       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.